Many patients have both Heart Failure (HF) and Chronic Obstructive Pulmonary Disease (COPD). Recent population-based registries indicate that spirometry is commonly not used to diagnosis concomitant COPD in patients with Heart Failure (HF) and that individuals with COPD frequently do not receive the advised Beta-Blocker (BB) medication. This cutting-edge review covers current issues with underusing and underdoing BBs in patients with HF and COPD despite guidelines' recommendations, as well as difficulties in applying advised spirometry for COPD diagnosis in patients with HF. The use of the nonselective BB carvedilol, target BB doses in patients with HF and COPD, BB and bronchodilator management during HF hospitalization with and without COPD exacerbation, and the use of BBs in COPD patients with right HF or free from cardiovascular disease are all open issues in the therapeutic management of patients with HF and COPD that are discussed in the third section. The entire case study presented here argues in favor of a bipartisan endeavor to draw immediate attention to the implementation of clinical practice recommendations from guidelines for patients with HF and co-occurring COPD.
